STOCK TITAN

Si-Bone - SIBN STOCK NEWS

Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.

Company Overview

Si-Bone Inc. is a specialized medical device company with a focused mission to improve patient outcomes in the realm of orthopedic surgery, particularly in the treatment of sacroiliac joint dysfunction. As a pioneer in the field, Si-Bone has developed a proprietary, minimally invasive implant system aimed at facilitating sacroiliac joint fusion. Leveraging patents for titanium implant technologies, the company has made significant strides in reducing the invasiveness of traditional sacroiliac joint fusion procedures.

Core Business and Innovation

At the heart of its operations, Si-Bone’s innovative approach is encapsulated in its iFuse Implant System, which is designed to provide a reliable alternative to conventional surgical techniques. The company has successfully combined advanced engineering with practical surgical approaches to produce a system that addresses complex conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, and pelvic trauma. The product portfolio includes instruments and implantable bone products that facilitate the fusion process during minimally invasive procedures, creating a distinct market niche with several industry-specific keywords such as minimally invasive surgery, orthopedic implants, and joint fusion.

Technological Advancements

Si-Bone separates itself from competitors through its commitment to technological innovation. The iFuse Implant System, along with its variations such as iFuse-TORQ and iFuse Bedrock Granite, incorporates breakthrough design and engineering principles to ensure safety and efficacy within complex anatomical regions. These devices are supported by rigorous clinical research and designed to provide enhanced pelvic fixation, particularly during concurrent lumbar spinal fusion procedures. This focus on precision technology underscores the company’s strategic positioning within the medical device market.

Clinical and Surgical Impact

The clinical implications of Si-Bone’s technology are noteworthy, especially for patients who have traditionally faced limited treatment options in the context of sacroiliac joint dysfunction. The minimally invasive nature of the iFuse Implant System offers advantages such as reduced recovery times, fewer complications compared to traditional open surgery, and a more targeted approach in addressing structural conditions. By improving the procedural experience for both patients and surgeons, Si-Bone plays a critical role in evolving standards of care in orthopedic surgery.

Market Position and Competitive Landscape

Si-Bone operates within a highly specialized sector of the medical device industry, marked by its focus on orthopedic applications. The company’s targeted approach to sacroiliac fusion procedures and its suite of patented implant products have carved a niche in an industry characterized by continuous innovation and rigorous safety standards. While there are other players in the broader field of orthopedic devices, Si-Bone differentiates itself by addressing the challenges associated with under-diagnosed and under-treated sacroiliac joint conditions using less invasive methods. The company’s seasoned management team, with experience from major industry names, further reinforces its authority and capability in driving orthopedic innovation.

Operational Excellence and Quality Assurance

Operating under stringent regulatory frameworks, Si-Bone emphasizes both the safety and effectiveness of its implant systems. The company’s operational strategy combines deep clinical expertise with advanced technological design, ensuring each product meets high standards of quality and efficacy. By integrating comprehensive research and development with real-world surgical feedback, Si-Bone is able to continuously refine its products, aiming to maintain robust patient safety profiles and reliable clinical outcomes.

Expertise and Industry Recognition

Si-Bone’s standing in the orthopedic device community is bolstered by its innovative approaches and the robust clinical data supporting its technologies. The company’s adoption of breakthrough design methods and its ability to translate complex medical needs into effective surgical solutions showcase its technical expertise. For healthcare professionals, patients, and stakeholders, Si-Bone represents a blend of advanced engineering, clinical precision, and a commitment to minimally invasive treatment paradigms, making it a respected name within its competitive landscape.

Comprehensive Product Portfolio

The diverse portfolio from Si-Bone is characterized by a range of implant systems designed to address various orthopedic conditions. It includes systems that directly target sacroiliac joint fusion as well as those that serve broader applications such as adjacent spinal conditions and pelvic trauma. This diversified approach allows clinicians to select devices tailored to the specific needs of their patients while maintaining consistency in surgical outcomes.

Conclusion

In summary, Si-Bone Inc. is an innovator in the orthopedic medical device space, focused on developing minimally invasive, patented implant systems for sacroiliac joint fusion and related applications. Through its continuous commitment to research, quality assurance, and operational precision, the company has established a strong market presence and a clear value proposition within a niche yet critically important segment of orthopedics. Its pioneering technologies, underscored by substantial clinical validation and a robust product portfolio, position it as an informative case study for anyone seeking a deep understanding of advanced orthopedic solutions.

Rhea-AI Summary

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management will host a fireside chat on August 14, 2024, at 3:30 p.m. Eastern Time.

Investors can listen to the conference call by registering through a provided link. The webcast will be available live on the 'Investors' section of SI-BONE's website and will be archived for at least 90 days after the event. This presentation offers an opportunity for investors to gain insights into SI-BONE's growth strategies and market position in the medical device industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq:SIBN) reported strong Q2 2024 financial results, with worldwide revenue reaching $40.0 million, a 20% increase year-over-year. U.S. revenue grew 21% to $37.8 million. The company improved its net loss by 20% to $8.9 million and reduced its Adjusted EBITDA loss by 43% to $2.7 million. SI-BONE ended the quarter with $151.5 million in cash and equivalents.

Operational highlights include a 23% increase in U.S. active physicians to over 1,150. The company also reported positive 5-year results from the SALLY clinical trial and early interim results from the STACI study. SI-BONE has increased its 2024 revenue guidance to $165-$167 million and expects to achieve positive Adjusted EBITDA in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company focused on musculoskeletal disorders of the sacropelvic anatomy, has announced it will release its second quarter 2024 financial results on August 5, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can register for the call using the provided link. A live audio webcast will be available on the company's website, and a replay will be accessible for at least 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
conferences earnings
Rhea-AI Summary

SI-BONE, a company specializing in solutions for musculoskeletal disorders, will present at the Truist Securities 2024 MedTech Conference in Boston on June 18, 2024. Management will hold a fireside chat at 3:40 p.m. ET / 12:40 p.m. PT. Investors can listen to the live webcast by registering through a provided link. The webcast will also be available on the company's website and archived for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
conferences
-
Rhea-AI Summary

SI-BONE, Inc. expands its product line with the launch of the Granite 9.5 implant, designed for sacroiliac fusion and spinopelvic fixation. The smaller diameter implant received FDA clearance in January 2024. Surgeons praise the implant for its ease of use and potential for improved patient outcomes. The company aims to target a large market with the new offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
none
-
Rhea-AI Summary

SI-BONE, Inc. reported financial results for the first quarter of 2024, showing worldwide revenue of $37.9 million, a 16% growth from the prior year. The company's U.S. revenue also increased by 16%, with a gross margin of 79%. SI-BONE is optimistic about revenue growth acceleration, driven by new product launches and market expansion. The company updated its 2024 revenue guidance to $164 million - $166 million, indicating a growth of 18% - 20%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
Rhea-AI Summary

SI-BONE, a medical device company dedicated to musculoskeletal disorders, will be presenting at the 2024 BofA Securities Healthcare Conference. Investors can join the fireside chat on May 14, 2024, at 2:20 p.m. Eastern Time. The webcast will be accessible for replay for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will report its first-quarter 2024 financial results on May 6, 2024. The company focuses on musculoskeletal disorders of the sacropelvic anatomy. The conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can register to listen to the call via a provided link. The webcast will be available on the company's website for replay for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences earnings
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will be participating in the Barclays 26th Annual Global Healthcare Conference. They will host a fireside chat on March 12, 8:30 a.m. EST. Investors can register to listen to the conference call online. The webcast will be available on the company's website for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
Rhea-AI Summary
SI-BONE, Inc. (SIBN) reported strong financial results for Q4 and FY 2023, with worldwide revenue up by ~22% and ~31% respectively. The company achieved gross margins of ~74% in Q4 and ~79% in FY 2023. Despite an increase in operating expenses, the net loss improved by ~2% in Q4 and ~29% for the year. Adjusted EBITDA loss declined by ~16% in Q4 and ~48% for FY 2023. Cash and equivalents stood at ~$166 million as of December 31, 2023. The company expects a 17% to 19% year-over-year revenue growth for 2024, with a gross margin of ~78% and operating expenses growth of ~9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.53%
Tags

FAQ

What is the current stock price of Si-Bone (SIBN)?

The current stock price of Si-Bone (SIBN) is $13.92 as of April 9, 2025.

What is the market cap of Si-Bone (SIBN)?

The market cap of Si-Bone (SIBN) is approximately 560.0M.

What is the primary focus of Si-Bone?

Si-Bone specializes in developing and commercializing innovative, minimally invasive implant systems designed for sacroiliac joint fusion, addressing complex orthopedic conditions.

How does the iFuse Implant System benefit patients?

The iFuse Implant System offers a less invasive alternative to traditional sacroiliac joint fusion surgery, resulting in reduced recovery times and potentially fewer complications.

What types of conditions does Si-Bone target with its products?

Si-Bone addresses conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, pelvic trauma, and specific challenges associated with spinal deformity.

How does Si-Bone differentiate itself in the orthopedic device industry?

Si-Bone differentiates itself by focusing on a niche market with its patented, minimally invasive technologies and by leveraging a management team with deep industry expertise from leading orthopedic companies.

What are the key benefits of minimally invasive surgical systems?

Minimally invasive systems typically provide improved patient recovery experiences, reduced overall surgical trauma, and enhanced precision during implant procedures, which are all hallmarks of Si-Bone's approach.

How does Si-Bone ensure the quality and safety of its products?

Si-Bone integrates rigorous clinical research and strict quality assurance protocols into its design and manufacturing process, ensuring that its implant systems meet high standards of safety and efficacy.
Si-Bone

Nasdaq:SIBN

SIBN Rankings

SIBN Stock Data

559.96M
37.70M
3.09%
95.51%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA